Cancer related fatigue Fatigue due to malignant neoplastic disease ICD-10-CM R53.0 is grouped within Diagnostic Related Group (s) (MS-DRG v38.0): 947 Signs and symptoms with mcc
exhaustion and fatigue due to depressive episode ( F32.-) Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.
Medical record should have documentation about the type of fatigue such as due to age (senile fatigue), psychological or chronic (lasts more than 6 weeks). If it is not documented clearly, that can be coded as general fatigue R53.83.
Category R53.8 (malaise and fatigue) – There are chances coder may get confused with the term ‘malaise’. Both malaise and fatigue are common type of symptoms of a disease. Extreme tiredness is termed as fatigue and feeling of discomfort is termed as malaise. Both codes come under same category R53.8 Malaise — R53.81
ICD-10-CM Code for Other malaise and fatigue R53. 8.
ICD-10 code Z92. 21 for Personal history of antineoplastic chemotherapy is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .
ICD-10 code R53. 82 for Chronic fatigue, unspecified is a medical classification as listed by WHO under the range - Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified .
T45. 1X5A - Adverse effect of antineoplastic and immunosuppressive drugs [initial encounter] | ICD-10-CM.
9: Fever, unspecified.
Antineoplastic drugs are medications used to treat cancer. Other names for antineoplastic drugs are anticancer, chemotherapy, chemo, cytotoxic, or hazardous drugs.
Chronic fatigue syndrome (CFS) is a complicated disorder characterized by extreme fatigue that lasts for at least six months and that can't be fully explained by an underlying medical condition. The fatigue worsens with physical or mental activity, but doesn't improve with rest.
ICD-10 code M62. 81 for Muscle weakness (generalized) is a medical classification as listed by WHO under the range - Soft tissue disorders .
2022 ICD-10-CM Diagnosis Code R53: Malaise and fatigue.
Chemotherapy can cause fatigue, loss of appetite, nausea, bowel issues such as constipation or diarrhoea, hair loss, mouth sores, skin and nail problems. You may have trouble concentrating or remembering things. There can also be nerve and muscle effects and hearing changes.
810 for Antineoplastic chemotherapy induced pancytopenia is a medical classification as listed by WHO under the range - Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism .
Myelosuppression — also referred to as bone marrow suppression — is a decrease in bone marrow activity resulting in reduced production of blood cells. This condition is a common side effect of chemotherapy. It can range from mild to severe. Severe myelosuppression, called myeloablation, can be fatal.
Extreme tiredness is termed as fatigue and feeling of discomfort is termed as malaise. Both codes come under same category R53.8. Malaise — R53.81.
Other symptoms may include muscle weakness, fever, sore throat, headache and joint pain.
Physical fatigue – Person is physically experiencing extreme tiredness and muscle weakness. This makes it difficult to perform daily activities which were done easily before. Mental fatigue – Here the person is unable to concentrate in anything and feels the brain is not working at all.
Fatigue – R53.82, R53.83 (chronic) Medical record should have documentation about the type of fatigue such as due to age (senile fatigue), psychological or chronic (lasts more than 6 weeks). If it is not documented clearly, that can be coded as general fatigue R53.83.
Code R53.83 is the diagnosis code used for Other Fatigue. It is a condition marked by drowsiness and an unusual lack of energy and mental alertness. It can be caused by many things, including illness, injury, or drugs.
ICD-10 codes are the byproduct of that revision. This medical classification list is generated by the World Health Organization (WHO), and is used to help healthcare providers identify and code health conditions. ICD-10 is required for use by physicians and healthcare providers under the Health Insurance Portability & Accountability Act (HIPAA) ...
198.7 Metastasis to adrenal gland 198.5 Metastasis to bone and/or marrow 198.3 Metastasis to brain and/or spinal cord 197.7 Metastasis to liver 197.0 Metastasis to lung 196.9 Metastasis to lymph nodes NOS 198.4 Metastasis to meninges (carcinomatous meningitis) 197.3 Metastasis to pleura (malignant effusion) 197.6 Metastasis to retro/peritoneum
Note that billing codes with a * are not billable without the extra digit, which usually specifies anatomic distribution in the case of lymphoma.
V42.81 Bone marrow replaced by transplant (post-transplant) 996.85 Complications bone marrow transplant (e.g graft vs. host) V59.3 Donor, bone marrow V59.02 Donor, blood stem cells V42.82 Peripheral stem cells replaced by transplant (post-transplant)
When a primary malignancy has been previously excised or eradicated from its site and there is no further treatment directed to that site and there is no evidence of any existing primary malignancy at that site, a code from category Z85, Personal history of malignant neoplasm, should be used to indicate the former site of the malignancy. Any mention of extension, invasion, or metastasis to another site is coded as a secondary malignant neoplasm to that site. The secondary site may be the principal or first-listed with the Z85 code used as a secondary code.
There are also codes Z85.6, Personal history of leukemia, and Z85.79, Personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissues. If the documentation is unclear as to whether the leukemia has achieved remission, the provider should be queried.
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion '), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous such as tumors in different quadrants of the same breast, codes for each site should be assigned.
Chapter 2 of the ICD-10-CM contains the codes for most benign and all malignant neoplasms. Certain benign neoplasms , such as prostatic adenomas, may be found in the specific body system chapters. To properly code a neoplasm, it is necessary to determine from the record if the neoplasm is benign, in-situ, malignant, or of uncertain histologic behavior. If malignant, any secondary ( metastatic) sites should also be determined.
Code C80.0, Disseminated malignant neoplasm, unspecified, is for use only in those cases where the patient has advanced metastatic disease and no known primary or secondary sites are specified. It should not be used in place of assigning codes for the primary site and all known secondary sites.
When a pregnant woman has a malignant neoplasm, a code from subcategory O9A.1 -, malignant neoplasm complicating pregnancy, childbirth, and the puerperium, should be sequenced first, followed by the appropriate code from Chapter 2 to indicate the type of neoplasm. Encounter for complication associated with a neoplasm.
Code C80.1, Malignant ( primary) neoplasm, unspecified, equates to Cancer, unspecified. This code should only be used when no determination can be made as to the primary site of a malignancy. This code should rarely be used in the inpatient setting.